Your browser doesn't support javascript.
loading
A feasibility study of the Xpert MTB/RIF test at the peripheral level laboratory in China.
Ou, Xichao; Xia, Hui; Li, Qiang; Pang, Yu; Wang, Shengfen; Zhao, Bing; Song, Yuanyuan; Zhou, Yang; Zheng, Yang; Zhang, Zhijian; Zhang, Zhiying; Li, Junchen; Dong, Haiyan; Chi, Junying; Zhang, Jack; Kam, Kai Man; Huan, Shitong; Jun, Yue; Chin, Daniel P; Zhao, Yanlin.
Afiliación
  • Ou X; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Xia H; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Li Q; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Pang Y; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Wang S; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Zhao B; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Song Y; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Zhou Y; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Zheng Y; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China.
  • Zhang Z; Respiratory Diseases Department of Nanlou, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Zhang Z; PATH, China Office, Beijing, China.
  • Li J; PATH, China Office, Beijing, China.
  • Dong H; PATH, China Office, Beijing, China.
  • Chi J; Bill and Melinda Gates Foundation, China Office, Beijing, China.
  • Zhang J; PATH, China Office, Beijing, China.
  • Kam KM; Stanley Ho Centre for Emerging Infectious Diseases, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China.
  • Huan S; Bill and Melinda Gates Foundation, China Office, Beijing, China.
  • Jun Y; Department of Clinical Laboratory, Shang Hai Pulmonary Disease Hospital, Shanghai, China.
  • Chin DP; Bill and Melinda Gates Foundation, China Office, Beijing, China. Electronic address: daniel.chin@gatesfoundation.org.
  • Zhao Y; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, No. 155, Changbai Road, Beijing, China. Electronic address: zhaoyanlin@chinatb.org.
Int J Infect Dis ; 31: 41-6, 2015 Feb.
Article en En | MEDLINE | ID: mdl-25447720
ABSTRACT

OBJECTIVE:

To evaluate the performance of Xpert MTB/RIF (MTB/RIF) in the county-level tuberculosis (TB) laboratory in China.

METHODS:

From April 2011 to January 2012, patients with suspected multidrug-resistant tuberculosis (MDR-TB) and non-MDR-TB were enrolled consecutively from four county-level TB laboratories. The detection of Mycobacterium tuberculosis (MTB) by MTB/RIF was compared to detection by Löwenstein-Jensen culture. The detection of rifampin resistance was compared to detection by conventional drug-susceptibility testing. The impact of multiple specimens on the performance of MTB/RIF was also evaluated.

RESULTS:

A total of 2142 suspected non-MDR-TB cases and 312 suspected MDR-TB cases were enrolled. For MTB detection in suspected non-MDR-TB cases, the sensitivity and specificity of MTB/RIF were 94.4% and 90.2%, respectively. The sensitivity in smear-negative patients was 88.8%. For the detection of rifampin resistance in suspected non-MDR-TB cases, the sensitivity and specificity of MTB/RIF were 87.1% and 97.9%, respectively. For the detection of rifampin resistance in suspected MDR-TB cases, the sensitivity and specificity of MTB/RIF were 87.1% and 91.0%, respectively. Using multiple sputum specimens had no significant influence on the performance of MTB/RIF for MTB detection.

CONCLUSIONS:

The introduction of MTB/RIF could increase the accuracy of detection of MTB and rifampin resistance in peripheral-level TB laboratories in China. One single specimen is adequate for TB diagnosis by MTB/RIF.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Reacción en Cadena en Tiempo Real de la Polimerasa / Mycobacterium tuberculosis Tipo de estudio: Clinical_trials / Diagnostic_studies / Evaluation_studies Límite: Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2015 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Reacción en Cadena en Tiempo Real de la Polimerasa / Mycobacterium tuberculosis Tipo de estudio: Clinical_trials / Diagnostic_studies / Evaluation_studies Límite: Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Int J Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2015 Tipo del documento: Article País de afiliación: China